GGrantScoutHQCreate alert
OPENVerified record

NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)

National Institutes of Health

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated mid-phase clinical trials of natural products(i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural produc

Funding
Estimated total program funding: $350,000
Deadline
November 14, 2026
Status
OPEN
Category
Health & Medical
Opens
December 2, 2024
Directory link check
October 27, 2026

About this opportunity

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated mid-phase clinical trials of natural products(i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. All applications submitted under this NOFO must be supported by sufficient preliminary data demonstrating bioavailability (if applicable) and documentation that the natural product produces a reproducible and measurable impact on target engagement (i.e., measure of the mechanism of action). Only in cases when it is not possible/practical to measure target engagement in the patient population of interest or when there is a fundamental understanding of the products mechanism of action will this preliminary data requirement be waived. Applications submitted to this NOFO should propose a mid-phase clinical trial to do the following: determine the optimal dose or formulation of a given natural product for use in a future multi-site efficacy trial; or determine which patient phenotypes will be responders versus non-responders to the natural product to inform inclusion/exclusion criteria of a future efficacy trial. Clinical trials submitted under this NOFO are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This NOFO will not support single-site or multi-site efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NO

Eligibility recorded

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Applicant types

Focus areas

Health

Recorded notice evidence

What to verify for NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)

Applicant evidence

  • Applicant type: State governments
  • Applicant type: County governments
  • Applicant type: City or township governments
  • Applicant type: Special district governments
  • Applicant type: Independent school districts
  • Applicant type: Public and state-controlled institutions of higher education
  • Applicant type: Federally recognized tribal governments
  • Applicant type: Public housing authorities and Indian housing authorities

Opportunity boundaries

  • Recorded funding: Estimated total program funding: $350,000
  • Recorded deadline: November 14, 2026; confirm the closing time.
  • Recorded focus: Health
Connect every eligibility claim, registration, attachment and deadline to the current notice. Open the specific official notice →

Application checklist

How to evaluate and apply for NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)

Use this record for discovery, then connect every requirement and date to the current official notice and its amendments.

Recorded applicant fit

State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and state-controlled institutions of higher education

Recorded geography

No structured geographic scope is recorded.

Recorded deadline

November 14, 2026 — confirm the closing time.

Eligibility summary: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Recorded focus: Health

1Confirm fitMatch entity type, location, project scope, exclusions and cost share.
2Read the noticeCollect amendments, budget rules, attachments and portal instructions.
3Plan timingRecord the funder’s time zone, registrations and internal review dates.
4Submit officiallyUse the funder’s route and save the submission confirmation.

Official sources

Directory link check: October 27, 2026. Always recheck the live notice before relying on it.

Continue researching

Related current grants

All Health & Medical grants →
OPENHealth & Medical

OJJDP FY 2026 Juvenile Drug Treatment Court Program

Office of Juvenile Justice Delinquency Prevention

This is a notice of funding opportunity (NOFO) for the OJJDP FY 2026 Juvenile Drug Treatment Court Program. This opportunity will support states, state and local courts, units of local government, and federally recognized Tribal governments to implement new or enhance existing juvenile drug treatmen

Deadline
Oct 30, 2026
Funding
Estimated total program funding: $4,000,000
Check fit and official source →
OPENHealth & Medical

BJA FY 2026 Adult Treatment Court Program

Bureau of Justice Assistance

This is a notice of funding opportunity (NOFO) for the BJA FY2026 Adult Treatment Court Program. This opportunity supports the implementation and enhancement of Adult Treatment Court (ATC) operations to prevent overdoses and reduce the use of opioids, stimulants, and other substances by high-risk/hi

Deadline
Oct 31, 2026
Funding
Up to $2,500,000
Check fit and official source →
OPENHealth & Medical

HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required)

National Institutes of Health

The NIH Helping to End Addiction Long-term® (HEAL) Initiative is releasing this Notice of Funding Opportunity (NOFO) to support a phased mechanistic clinical research program focusing on understudied biological mechanisms that drive joint pain. The phased projects supported by this program (of

Deadline
Oct 31, 2026
Funding
See official notice
Check fit and official source →
OPENHealth & Medical

GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed)

National Institutes of Health

The Genomics Research to Elucidate the Genetics of Rare Diseases:innovation (GREGoRi) initiative seeks to accelerate a paradigm shift in rare disease diagnosis by reimagining the tools, molecular technologies and analytical approaches used to identify the causal gene(s) and/or variant(s) underlying

Deadline
Oct 31, 2026
Funding
Estimated total program funding: $2,000,000
Check fit and official source →